Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilisation. However, considerable variation in their use and...
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for...
Peter Kekenes-Huskey, Andrew McCulloch, Rommie Amaro and Johan Hake
April 03, 2015
Washington University School of Medicine
Frontiers Review Editor
Michigan State University
East Lansing, USA
© 2007 -
Frontiers Media S.A. All Rights Reserved